RxDoctor Payments DataLook up a doctor →

Andrei Pop, MD

Interventional Cardiology · Elk Grove Village, ILNPI 1417156365

Payments from drug & device makers

$1,853,988in general payments, 2019–2025

Across 1,139 payments — averaging $1627.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1.7M
  • Inari Medical, Inc.$62K
  • Endologix LLC$41K
  • W. L. Gore & Associates, Inc.$19K
  • Shockwave Medical, Inc$15K
  • Abbott$4K
  • plus $13K from 28 others
$3,102in research payments, 2019–2025

Across 5 payments — averaging $620.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cook Research Incorporated$3K

What the payments were for

  • Consulting fees$667,83774%
  • Speaking & faculty fees$97,83811%
  • Travel & lodging$98,91411%
  • Food & beverage$33,9234%
  • Education$1,7700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,853,988 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$331,939
Medicare patients
733
Services billed
2,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$110,321
XareltoRivaroxaban32$49,127
BrilintaTicagrelor24$25,298
Repatha SureclickEvolocumab13$9,452
Atorvastatin Calcium418$4,782
Ezetimibe146$3,767
Carvedilol290$2,782
Metoprolol Succinate158$2,648
Rosuvastatin Calcium110$1,904
ClopidogrelClopidogrel Bisulfate94$905
Lisinopril119$899
Cilostazol27$897
Chlorthalidone74$842
Enalapril Maleate41$834
Amlodipine Besylate122$695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$19$49,12732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Elk Grove Village

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →